Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Andreas von Planta 
        • Charles Sawyers 
        • William Winters 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Marie-France Tschudin 
        • Lutz Hegemann 
        • Kees Roks 
        • Richard Saynor 
        • Michael Willi 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Innovative Medicines 
      • Sandoz 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and Recognition 
      Male scientist in lab About Novartis
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • COVID-19: Patients and Caregivers 
      • Stories: Patients Perspectives 
      Couple holding hands Patients & Caregivers
    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
        • Abstract summaries for EADV 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor Healthcare Professionals
    • Research & Development 
      • Novartis Institutes for BioMedical Research 
        • Collaborations 
        • NIBR Global Scholars Program 
      • Technology Platforms 
        • Radioligand Therapy 
        • Gene Therapy 
        • Cell Therapy 
      • Research Disease Areas 
        • Immuno-oncology research at Novartis 
        • Oncology research at Novartis 
        • Cardiovascular and metabolic disease research at Novartis 
        • Autoimmunity, transplantation and inflammatory disease research at Novartis 
        • Ophthalmology research at Novartis 
        • Neuroscience Research at Novartis 
        • Musculoskeletal Disease Research at Novartis 
        • DAx: exploratory disease research at Novartis 
      • Research Locations 
        • Novartis Institute for Tropical Diseases 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research & Development Approach 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments Research & Development
    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Anti-Microbial Resistance (AMR) 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity, Equity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda Environmental, Social and Governance
    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube Investors
    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens News
    • Careers 
      • Career Search 
      • Our Teams 
        • Careers in Commercial 
        • Careers in Communications and Engagement 
        • Careers in Consulting 
        • Careers in Digital 
        • Careers in Health, Safety & Environment 
        • Careers in Information Technology (IT) 
        • Careers in Medical & Development 
        • Careers in People & Organization 
        • Careers in Procurement 
        • Careers in Research 
        • Careers in Strategy 
        • Careers in Manufacturing and Supply 
        • Ethics, Risk & Compliance (ERC) 
        • Careers in Legal 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Talent 
        • US NIBR Internship Programs 
      • International Careers 
      • Personal Growth 
      • Well-being 
      A female Novartis researcher Careers
    • Clinical Trials 
      doctor taking the blood pressure of her patient Clinical Trials
    • Partnering 
      Business people working in a dark room Partnering
    • Supplier Portal 
    • Report side effects 
    • Contacts 
      Office Cubicle Contacts
    Group of scientists working in a lab in winter Home
  • People and Culture
    A scientist from the start – Q&A with NIBR President Fiona Marshall
    Biomedical ResearchNovartis Institutes for BioMedical ResearchScientific ResearchDrug DevelopmentWomen in Science
  • People and Culture
    In neuroscience, “an inflection point in knowledge and technology”
    Drug DiscoveryNeurodegenerative DiseaseNeuroscienceNovartis Institutes for BioMedical ResearchScientific Research
  • Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
    Basel, March 8, 2022 — Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.
    Scientific ResearchNeuroscienceNeurodegenerative Disease
  • From Our Labs
    When it comes to cancer, there’s power in a good partner

    Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

    CancerClinical ResearchInnovationOncologyScientific Research
  • Discovery
    Stopping this coronavirus – and the next one

    Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.

    Biomedical ResearchCOVID-19Drug DiscoveryNovartis Institutes for BioMedical ResearchScientific Research
  • Discovery
    Solving the puzzle of immunotherapy

    From an eccentric idea to a revolution in medicine – the history of immunotherapy and a peek into its future.

    CancerInnovationScientific ResearchOncology
  • Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
    Basel, November 5, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA)…
    Scientific ResearchInnovationDrug Discovery
  • Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
    Basel, November 6, 2020 — Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)6. The ongoing trial failed to meet its primary endpoint…
    Scientific ResearchDrug Discovery
  • Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition
    Basel, December 17, 2020 — Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts based neuroscience company. The acquisition adds two new clinical stage programs to the Novartis neuroscience portfolio, one for schizophrenia and the other for movement disorders. The agreement also includes a buyout of…
    Scientific ResearchScientific DiscoveriesReimagine Medicine
  • Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
    Basel, December 9, 2019 — “We see sickle cell as a painful disease, but too often we don't translate how that pain affects the lives of our patients – can they go to school, can they work, can they enjoy their families? These are things many of us take for granted,” said Ifeyinwa Osunkwo, MD, MPH, Founder and Director, Sickle Cell Disease…
    Tropical DiseasesScientific ResearchAfrica
  • Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
    Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify…
    Social CommitmentScientific ResearchReimagine Medicine
  • Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
    Basel, April 20, 2020 — Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz,…
    Social CommitmentScientific ResearchInfectious Diseases

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience